drugset / Trial / NCT00576251

TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension

NCT00576251

Phase 3 Completed 221 enrolled Alcon Research
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to describe the differences in efficacy between TOBRADEX Ophthalmic Suspension and Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension in the treatment of ocular inflammation and infection associated with blepharaconjunctivitis

Timeline

Start
2007-10
Primary completion
2008-02
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Background Dexamethasone Small molecule 0.05 % Other
Background Tobramycin Small molecule 0.3 % Other